Gene Editing

Heavyweights By Sharon Begley

George Church has a wild idea to upend evolution. Here’s your guide

Business By Damian Garde

Gene-editing biotech Intellia files for $120 million IPO

In the Lab By Carl Zimmer

Inside the secret defense systems of giant viruses

Business By Andrew Joseph

A billion-dollar patent fight over gene editing hits the courts

In the Lab By Charles Piller

California considers funding controversial research: editing genes in human embryos

In the Lab By Andrew Joseph

UK government agency approves editing genes in human embryos

Lab Chat By Megan Thielking

Using CRISPR to edit out blindness

In the Lab By Sharon Begley

Controversial CRISPR history sets off an online firestorm

In the Lab By Andrew Joseph and Sharon Begley

God, malaria, and wolverine claws: Colbert talks CRISPR with George Church

Business By Robert Weisman — Boston Globe

Startup Editas plans to test IPO market for biotechs

In the Lab By Carl Zimmer

Science in 2016: Separating the hype from the promise

Business By Andrew Joseph

Cambridge researchers wade into gene-editing debate

First Opinion By Patrick Skerrett

A debate: Should we edit the human germline?

In the Lab By Sharon Begley

Gene drive gives scientists power to hijack evolution

First Opinion By Patrick Skerrett

Experts debate: Are we playing with fire when we edit human genes?

Politics By Sharon Begley

Most Read

Alarmed by new ‘CRISPR babies’ plan, top science figures say they’re powerless to stop it

Are scientists’ reactions to ‘CRISPR babies’ about ethics or self-governance?

The West is losing the gene editing race. It needs to catch up

Watch: As it moves out of the lab, CRISPR brings tough questions into the clinic

Preclinical biotech companies are having an IPO bonanza. What’s the draw for investors?

What will 2018 bring for science and medicine? We asked the experts

Startup Spotlight: Playing Pac-Man with CRISPR

Oral arguments set to begin next month in major CRISPR patent case

All Coverage